IL17A and plasma cell myeloma: In patients with multiple myeloma, serum as well as bone marrow levels of IL-27 decrease whilst IL-17 increases in line with disease progression, with a high IL-27 : IL-17 ratio (i.e., high IL-27 and low IL-17) in the bone marrow associated with better prognosis [144].